Affordable Access

deepdyve-link
Publisher Website

Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019.

Authors
  • Zhao, Juanjuan1
  • Yuan, Quan2, 3
  • Wang, Haiyan1
  • Liu, Wei2, 3
  • Liao, Xuejiao1
  • Su, Yingying2, 3
  • Wang, Xin1
  • Yuan, Jing4
  • Li, Tingdong2, 3
  • Li, Jinxiu5
  • Qian, Shen1
  • Hong, Congming2, 3
  • Wang, Fuxiang4
  • Liu, Yingxia4, 6
  • Wang, Zhaoqin6
  • He, Qing6
  • Li, Zhiyong3
  • He, Bin2, 3
  • Zhang, Tianying2, 3
  • Fu, Yang7
  • And 5 more
  • 1 Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, China. , (China)
  • 2 The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health and School of Life Science, Xiamen University, Xiamen, China. , (China)
  • 3 School of Public Health, Xiamen University, Xiamen, China. , (China)
  • 4 Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, China. , (China)
  • 5 Department of Critical Care Medicine, Shenzhen Third People's Hospital, Shenzhen, China. , (China)
  • 6 The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, China. , (China)
  • 7 School of Medicine, Southern University of Science and Technology, Shenzhen, China. , (China)
Type
Published Article
Journal
Clinical Infectious Diseases
Publisher
Oxford University Press
Publication Date
Nov 19, 2020
Volume
71
Issue
16
Pages
2027–2034
Identifiers
DOI: 10.1093/cid/ciaa344
PMID: 32221519
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patients remains largely unknown, and the clinical value of antibody testing has not been fully demonstrated. 173 patients with SARS-CoV-2 infection were enrolled. Their serial plasma samples (n = 535) collected during hospitalization were tested for total antibodies (Ab), IgM, and IgG against SARS-CoV-2. The dynamics of antibodies with disease progress were analyzed. Among 173 patients, the seroconversion rates for Ab, IgM, and IgG were 93.1%, 82.7%, and 64.7%, respectively. The reason for the negative antibody findings in 12 patients might be due to the lack of blood samples at the later stage of illness. The median seroconversion times for Ab, IgM, and then IgG were days 11, 12, and 4, respectively. The presence of antibodies was <40% among patients within 1 week of onset, and rapidly increased to 100.0% (Ab), 94.3% (IgM), and 79.8% (IgG) by day 15 after onset. In contrast, RNA detectability decreased from 66.7% (58/87) in samples collected before day 7 to 45.5% (25/55) during days 15-39. Combining RNA and antibody detection significantly improved the sensitivity of pathogenic diagnosis for COVID-19 (P < .001), even in the early phase of 1 week from onset (P = .007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (P = .006). Antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients. © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected]

Report this publication

Statistics

Seen <100 times